Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Bullish On Januvia Prospects Despite Soft First Quarter Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharma company sees plenty of potential for its top-selling drug even as its sales came in weak during the first quarter. Meanwhile, Merck welcomes its new head of R&D and the potential for change.

You may also be interested in...



Emerging Markets Earnings Roundup: Pfizer And Merck (Part 5)

Pfizer and Merck have more than a deal on a diabetes candidate in common as both companies saw foreign exchange and patent expiries hit the bottom line in the first quarter and see emerging markets as key growth drivers this year.

Pfizer Posts Weak First Quarter As It Continues To Mull Over A Split

The Big Pharma disappoints investors with a weak first quarter and a failure to come to any decisions about the future structuring of the company. Meanwhile, the company made little progress of note during the quarter.

Merck And Pfizer Make A Late Play For The Diabetes Market

Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel